US$ 29.97
glp-1/gip/glucagon receptor agonist Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Possible mechanisms of action of
Description
This product was approved for the treatment of T2DM

Pediatric and Adolescent Obesity Treatment: Since FDA approval in 2022, GLP-1 receptor agonists have been prescribed for individuals aged 12 years and older with obesity (BMI 95th percentile)

Hunt, J

Surgical Endoscopy

As shown by Sun et al., treatment with GLP-1RAs reshaped gut microbial composition by increasing the abundance of beneficial genera such as Lactobacillus and Bifidobacterium

Insulin resistance and Parkinsons disease: A new target for disease modification
